Funding for this research was provided by:
Bristol Myers Squibb Pharmaceuticals Ltd.
Received: 23 March 2020
Accepted: 8 July 2020
First Online: 17 July 2020
Ethics approval and consent to participate
: Ethics approval was granted by the UK’s Health Research Authority (HRA) on 24 November 2016 [IRAS ID: 209130]. The HRA approved the protocol for this study and agreed that patient consent was not required because the study was a retrospective chart review study using anonymised data.
: Not applicable.
: REH: Advisory Boards: ESAI, Ipsen, Pfizer, EUSA, Roche, Novartis, BMS. Shareholder/Founder Immetacyte Ltd., Royalties from MRC for Phage Antibody patents.KF: Advisory boards: ESAI, IPSEN, Roche, Novartis; Speaker fees/consultancy: BMS, Pfizer.TE is on part-time leave of absence from the University of Cambridge to work in AstraZeneca. He has received research support from Pfizer, Bayer and AstraZeneca. He holds stock in AstraZeneca.AM is an employee of AstraZeneca.